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Transforming growth factor-1 (TGF-1) is established to be involved in the
pathogenesis of diabetic nephropathy. The diabetic milieu enhances oxidative stress
and induces the expression of TGF-1. TGF-1 promotes cell hypertrophy and
extracellular matrix accumulation in the mesangium, which decreases glomerular
filtration rate and leads to chronic renal failure. Recently, TGF-1 has been
demonstrated to regulate urinary albumin excretion by both increasing glomerular
permeability and decreasing reabsorption in the proximal tubules. TGF-1 also
increases urinary excretion of water, electrolytes and glucose by suppressing
tubular reabsorption in both normal and diabetic conditions. Although TGF-1
exerts hypertrophic and fibrogenic effects in diabetic nephropathy, whether sup-
pression of the function of TGF-1 can be an option to prevent or treat the
complication is still controversial. This is partly because adrenal production of
mineralocorticoids could be augmented by the suppression of TGF-1. However,
differentiating the molecular mechanisms for glomerulosclerosis from those for the
suppression of the effects of mineralocorticoids by TGF-1 may assist in devel-
oping novel therapeutic strategies for diabetic nephropathy. In this review, we
discuss recent findings on the role of TGF-1 in diabetic nephropathy.
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TRANSFORMING GROWTH FACTOR-1 (TGF-1) is a multifunc-
tional cytokine that controls numerous biological processes
including immunity (92), differentiation (29), tumor sup-
pression (2), tumor metastasis (107), senescence (68), mi-
gration (17), wound healing (105), apoptosis (108), cell
division (2), adipogenesis (76), and osteogenesis (27). In
addition, the renal expression of TGF-1 mRNA and protein
are increased in patients with diabetes mellitus (110), and it
enhances the synthesis and cross-linking of extracellular
matrix (ECM) (3, 81).
In the US population, the most frequent cause of chronic
renal failure is diabetes mellitus (44%). No more than
2040% of diabetic subjects, however, develop nephropathy
despite having similar blood glucose levels, suggesting the
presence of genetic predisposition to the complication. The
T869C polymorphism in the human TGF-1 gene, leading to
the L10P variant of the coding protein, is associated with an
increased risk of diabetic nephropathy (71, 77, 109), but how
the functional change in TGF-1 protein increases the inci-
dence of diabetic nephropathy remains elusive.
In incipient diabetic nephropathy, the glomerular filtration
rate (GFR) increases by 2550% (glomerular hyperfiltration)
(1) by the reduction of tubuloglomerular feedback, which is
caused by the increase in sodium/glucose reabsorption and
hence the reduced sodium delivery in the macula densa (101).
However, in the late stage of diabetic nephropathy, the GFR
eventually declines as the number of functional nephrons
decreases, which leads to the insufficiency of renal excretory
function. The decline in GFR is associated with the expansion
of mesangial area, which is caused by cell proliferation and
accumulation of ECM.
Although the increase in urinary excretion of albumin is
considered to be the early indicator of diabetic nephropathy,
the mechanisms whereby hyperalbuminuria occurs in diabetic
subjects are not fully understood. However, impairment of
barrier function at the slit diaphragm between podocytes and
the decrease in reabsorption of filtered albumin by proximal
tubules have recently been identified as pivotal in the devel-
opment of diabetic albuminuria.
Mice having the heterozygous Akita diabetogenic mutation
expressing 10, 50, 100, 200, and 300% normal Tgfb1 mRNA
levels have recently been generated. In these mice, the severity
of glomerulosclerosis and albuminuria is enhanced as the
expression of TGF-1 is increased, despite blood pressure
being negatively correlated with TGF-1 expression (31). It is
noteworthy that the diabetic mice with 10% normal TGF-1
expression exhibit near-normal glomerular histology, GFR,
and urinary albumin excretion, despite the presence of primary
aldosteronism and hypertension. Additionally, the markedly
increased urinary excretion of water, electrolytes, and glucose
in Akita type 1 diabetes was diminished to levels comparable
to those in nondiabetic wild-type mice by the genetic insuffi-
ciency of TGF-1.
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These previous findings suggest that TGF-1 plays a patho-
physiological role not only in promoting glomerulosclerosis,
interstitial fibrosis, and the decline in GFR but also in increas-
ing urinary excretion of albumin, water, electrolytes, and
glucose in diabetes. In the current review, we will discuss the
mechanisms whereby TGF-1 causes renal morphological and
functional changes in diabetes mellitus. As such, therapeutic
strategies targeting TGF- signaling may be developed to
effectively treat chronic excretory insufficiency in patients with
diabetes.
TGF-1 Facilitates Accumulation of ECM in Diabetic
Nephropathy
Previous studies show that neutralizing anti-TGF- antibod-
ies prevented glomerulosclerosis and interstitial fibrosis, and
reduced expression of ECM genes including fibronectin and
type IV collagen in mice with type 1 and type 2 diabetes (90,
116), suggesting that TGF- signaling plays a critical role in
ECM accumulation in diabetic nephropathy. Both canonical
and alternative signaling of TGF-1 have been suggested to be
involved in the development of diabetic nephropathy (15, 19).
Since glucose availability is impaired in diabetes, the met-
abolic shift occurs from glycolysis toward oxidative phosphor-
ylation by using more fatty acids as an energy source (Fig. 1).
As a result, the mitochondrial electron transport chain in-
creases superoxide production and stimulates three major path-
ways of hyperglycemic damage (activation of the polyol path-
way, advanced glycation end products generation, and protein
kinase C activation) (72). Furthermore, high glucose induces
reactive oxygen species (ROS) via NAD(P)H oxidase, mito-
chondrial electron transport chain, and protein kinase C (56).
Hydrogen peroxide upregulates TGF-1 and its downstream
ECM-related genes, including integrin-linked kinase, fibronec-
tin, and collagen types I, III, and IV (25, 48). In the reverse
direction, pharmacological inhibition of different ROS sources
including NAD(P)H oxidase and mitochondrial respiratory
chain decreases the transcription of TGF-1 via reduced ac-
tivity of activated protein-1 (26), indicating that ROS-induced
enhancement of the transcription of TGF-1 may at least in
part account for the increase in TGF-1 expression in diabetes.
Previous studies have demonstrated that TGF-1 stimulates
the transcription of the components of ECM, including colla-
gen, fibronectin, and laminin (5, 41). It has been demonstrated
that TGF-1 also increases the expression of lysyl oxidase,
which forms cross-links between collagen and elastin fibers
that stabilizes their structure (3). TGF-1 also stimulates the
transcription of procollagen lysyl hydroxylase 2, which hy-
droxylates lysyl residues of collagen telopeptides and is essen-
tial for collagen cross-linking (24). In addition, TGF-1 aug-
ments the expression of plasminogen activator inhibitor-1 (39)
and tissue inhibitor of metalloproteinases-1 (100), both of
which inhibit the activity of ECM-degradating matrix metal-
loproteinases.
The effect of TGF-1 on the expression of matrix metallo-
proteinase 9 (MMP9) is controversial. TGF-1 increases the
expression of MMP9 in cultured cells and in isolated, perfused
kidneys (13, 82), whereas transgenic overexpression of
TGF-1 decreases MMP9 expression in mice (100, 112). The
exact reason for this discrepancy is unclear, but the suppressive
effect of TGF-1 on mineralocorticoid production may be
related. Previous studies have demonstrated that aldosterone
increases the transcription of MMP9 via phosphoinositide
3-kinase (PI3K), p38 MAPK, ERK (23), and oxidized Ca2/
calmodulin-dependent protein kinase II (oxCaMKII) (32), sug-
gesting that TGF-1 decreases tissue MMP9 expression via
suppressing circulating aldosterone produced in adrenocortical
cells.
Recently, TGF- type 1 receptor antagonists and aldoste-
rone have also been found to increase the expression of a
disintegrin and metalloproteinase with thrombospondin motifs
(ADAMTS)-1, which also degrades ECM (16, 54).
Thus TGF-1 facilitates ECM accumulation by increas-
ing production and stabilization of ECM and by suppressing
its degradation, which plays a causative role in developing
glomerulosclerosis and interstitial fibrosis in diabetic ne-
phropathy.
TGF-1 Facilitates Dedifferentiation of Renal Cells
Previous studies suggest that TGF-1 induces epithelial-
mesenchymal transition/transdifferentiation (EMT), a dediffer-
entiation process by which an epithelial cell is transformed into
a myofibroblast, a type of mesenchymal stem cell (96). In the
kidney, tubular cells are normally lining the tubular basement
membrane and have a highly polarized structure for efficient
reabsorption of solutes and proteins from urinary space into
peritubular capillaries, but through the EMT process they lose
cell polarity and gain migratory and fibrogenic properties of
myofibroblasts (35). Indeed, TGF-1 has been demonstrated to
induce EMT in proximal tubules (115), collecting duct cells
(43), glomerular podocytes (33, 88), and glomerular parietal
epithelial cells (93).
It has been demonstrated that hypoxia-inducible factor 1
(HIF-1) enhances EMT in murine proximal tubular epithelial
cells (34). Since the effect of hypoxia on EMT is only partially
inhibited by anti-TGF- antibodies, TGF- signaling is un-
likely to be the only mechanism to induce EMT (34). Prolyl
hydroxylase domain-containing proteins (PHDs) hydroxylate
HIF-1. Hydroxylated HIF-1 binds to von Hippel-Lindau
tumor suppressor protein and is subject to polyubiquitination
and degradation by proteasomes (44). TGF-1 has been shown
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Fig. 1. Diagram depicting the proposed effects of transforming growth fac-
tor-1 (TGF-1) on the features of diabetic nephropathy. ROS, reactive
oxygen species; EMT, epithelial-mesenchymal transition; EndMT, endotheli-
al-mesenchymal transition.
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to decrease both mRNA and protein levels of PHD2 and hence
stabilize HIF-1 protein (66). Overexpression of the HIF-1
PHD2 transgene, which enhances degradation of HIF-1, com-
pletely prevents TGF-1-induced changes in the expression of
HIF-1 and marker genes for EMT, suggesting that HIF-1
mediates TGF-1-induced EMT (30).
It has also been shown that TGF-1 activates the Jagged/
Notch signaling pathway and that activated Notch triggers
EMT (74). These results suggest that TGF-1-induced EMT is
also mediated at least in part by Jagged/Notch signaling.
Previous studies suggest that endothelial-mesenchymal tran-
sition/transdifferentiation (EndMT), a process by which endo-
thelial cells are transformed into myofibroblasts, also contrib-
utes to renal fibrosis in streptozotocin (STZ)-induced type 1
diabetic mice (113). TGF-1 has been demonstrated to induce
EndMT (114). Overexpression of Snail induced EndMT, but
suppression of Snail expression abrogated TGF-2-induced
EndMT in mouse endothelial cells, suggesting that Snail me-
diates TGF- signaling-induced EndMT (50).
Thus TGF-1 may be involved in the process of EMT and
EndMT in diabetic nephropathy, which decreases the number
of functional cells and increases the accumulation of ECM,
leading to impairment of renal excretory and reabsorptive
function. However, controversy remains over the contribution
of each of these processes to renal fibrosis (18).
TGF-1 Enhances Diabetic Albuminuria Via Both
Glomerular and Postglomerular Mechanisms
A number of previous studies have demonstrated that
TGF-1 promotes the development of diabetic albuminuria.
Several transgenic animal models overexpressing TGF-1 ex-
hibited increased urinary excretion of albumin (51, 100).
Chronic treatment with the soluble human TGF- type II
receptor reduced albuminuria without changing blood glucose
levels in STZ-induced diabetic mice (84). However, several
studies did not show a significant effect of the suppression of
TGF- signaling on albuminuria in diabetic animals. For
instance, chronic peritoneal infusion of neutralizing anti-
TGF- antibodies did not alter urinary albumin excretion in
db/db type 2 diabetic mice (116). Furthermore, genetic defi-
ciency of small mothers against decapentaplegic homolog
(Smad) 3, an intracellular signaling molecule which is down-
stream of TGF- receptors, did not affect albuminuria in
STZ-induced diabetic mice (104).
Microalbuminuria is low-grade albuminuria, which ranges
from 30 to 300 mg/day in humans, and is widely established as
an early indicator of diabetic nephropathy. However, whether
the elevated urinary excretion of albumin plays a causative role
in diabetic tubular damage or is merely a consequence of
diabetic nephropathy is still controversial (45).
The paradigm that the sieving of albumin at the slit dia-
phragm is the predominant mechanism in the prevention of
albuminuria has been questionable because of the lack of a
clearing mechanism of the sieved albumin (91). Indeed, the
concentration of albumin at Bowman’s capsule estimated with
two-photon microscopy has been demonstrated to be within the
nephrotic range (1–10 mg/ml) even in normal conditions (86).
In contrast, others using a micropuncture technique have re-
ported less concentrations of albumin (20–30 g/ml) than the
nephrotic range in Bowman’s capsule (53, 97). Nevertheless,
these results indicate that both incomplete glomerular barrier
and subsequent tubular reabsorption/degradation are important
in preventing albuminuria (10).
Nephrin is abundantly expressed in the slit diaphragm and
considered to exert a barrier function against glomerular fil-
tration of albumin (37, 106). The mutations in the nephrin gene
lead to urinary overexcretion of high-molecular-weight pro-
teins and albumin and congenital nephrotic syndromes (47,
79). However, tubular handling of protein is important as well.
Megalin and cubilin in the brush border of proximal tubular
cells contribute to the endocytosis of albumin and low-molec-
ular-weight proteins (9, 22, 58, 67, 111).
The expression of nephrin is decreased in diabetes (12).
TGF-1 decreases renal mRNA levels of nephrin (31) and
increases the permeability of albumin in the podocyte (55).
Additionally, the presence of diabetes attenuates the expression
of megalin (98). TGF-1 decreases renal megalin mRNA
levels in Akita type 1 diabetic mice (31), which might attenuate
the albumin endocytosis mediated by megalin (22).
Therefore, it is likely that diabetic albuminuria is the result
of a double insult in the kidney’s ability to process albumin,
increased permeability at the slit diaphragm, and reduced
tubular reabsorption. However, in what proportion diabetic
albuminuria is caused by tubular dysfunction and/or podocyte
dysfunction is controversial (75, 85, 98, 99).
Albuminuria in Akita mice expressing 10% TGF-1 mRNA
was markedly reduced compared with that in Akita mice and
was comparable to nondiabetic wild-type mice, despite similar
glucose levels and increased systolic blood pressure in the 10%
hypomorphic Akita mice (31). In the reverse direction, genetic
overexpression of TGF-1 markedly increased urinary albu-
min excretion despite no significant changes in blood glucose
or blood pressure (31). The amount of urinary albumin excre-
tion in the 10% hypomorphic Akita mice was found to be
increased by 20-fold by overexpressing Tgfb1 in proximal
tubular cells, but only by 4-fold by overexpressing Tgfb1 in
podocytes.
Thus TGF-1 plays a critical role in developing hyperalbu-
minuria. These findings demonstrate that attenuated tubular
reabsorption of albumin appears to be the predominant factor
leading to diabetic albuminuria, rather than enhanced glomer-
ular filtration.
TGF-1 Inhibits Production and Function of
Mineralocorticoids
Plasma levels of aldosterone are increased in diabetic pa-
tients (36), and aldosterone has been shown to increase ROS by
stimulating NAD(P)H oxidase (83). These findings suggest
that the increased action of mineralocorticoids partly contrib-
utes to the development of diabetic complications. Indeed,
chronic administration of spironolactone, a mineralocorticoid
receptor antagonist, decreased albuminuria in patients with
diabetes (89).
It has been shown that TGF-1 potently inhibits the synthe-
sis of aldosterone in vitro (28, 38, 61). TGF-1 also suppresses
the production of androstenedione, corticosterone, and cortisol
(38). This broad suppressive effect of TGF-1 on steroidogen-
esis may be partly because TGF-1 decreases the expression of
cytochrome P-450 side-chain cleavage (P450scc), adrenodoxin
reductase, and adrenodoxin, which controls the initial step of
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steroidogenesis (69). The mRNA levels for steroidogenic acute
regulatory protein (StAR), which supplies cholesterol to
P450scc by transporting it from the outer to the inner mito-
chondrial membrane, is also decreased by TGF-1 (4). In
bovine adrenocortical cells, TGF-1 also reduced the transcript
levels of hydroxyl-delta-5-steroid dehydrogenase, 3- and ste-
roid delta-isomerase 1 (Hsd3b1), and steroid 17--monooxy-
genase (Cyp17a1) (60).
It has recently been reported that TGF-1 decreases cortisol
and 11-hydroxyandrostenedione production induced by fors-
kolin by 85% and production of aldosterone induced by an-
giotensin II by 80%. The activity of steroid 11-hydroxylase
(Cyp11b1) and the transcript levels for Cyp11b1 induced by
forskolin, as well as the activity of aldosterone synthase
(Cyp11b2) and the transcript levels for Cyp11b2 induced by
angiotensin II, were strongly inhibited by TGF-1 in the
NCI-H295R cell line (61). TGF-1 suppressed Cyp11b1 pro-
moter activity, but the Smads-binding sequence was not re-
sponsible for the transcriptional inhibition. This result suggests
that TGF-1 indirectly represses Cyp11b1 promoter activity
(61). Intriguingly, the mRNA levels of steroidogenic factor 1,
the genetic deficiency of which causes the absence of gonadal
and adrenal steroidogenic cells (64), were inhibited by TGF-1
(59). Steroidogenic factor 1 binds to a shared promoter element
of steroidogenic enzymes, including Cyp11b1, Cyp11b2, ste-
roid 21-hydroxylase (Cyp21a1), and Cyp11a1 (80), and en-
hances their expression (52). Thus numerous steroidogenic
steps that are upstream of the synthesis of aldosterone are
suppressed by TGF-1.
Indeed, it has been shown that plasma levels of aldosterone
and the adrenal expression of several steroidogenic enzymes
involved in the production of aldosterone, including Cyp11b1,
Cyp11b2, Star, Hsd3b1, and Cyp21a1, are decreased as
TGF-1 expression is increased in mice having graded expres-
sion of TGF-1 (46). The suppressive effect of overexpression
of TGF-1 on plasma levels of aldosterone was also observed
in Akita diabetic mice (31).
Although TGF-1 exerts a suppressive effect on adrenocor-
tical production of aldosterone, the stimulatory effect of aldo-
sterone on the activity of epithelial sodium channel (ENaC) is
also inhibited by TGF-1. Aldosterone expands the volume of
extracellular fluid by increasing ENaC activity. ENaC is ex-
pressed in the “aldosterone-sensitive distal nephron,” which is
composed of collecting ducts, connecting tubules, and late
distal convoluted tubules (21, 62). The aldosterone-sensitive
distal nephron also expresses two other components required
for sodium reabsorption in response to aldosterone: Na-K-
ATPase and mineralocorticoid receptors.
Although aldosterone is the major regulator of ENaC activ-
ity, TGF-1 also regulates ENaC activity either in combination
with aldosterone or independently (6, 62). The aldosterone-
induced increase in sodium transport via the ENaC is inhibited
by TGF-1 (40). TGF-1 enhances -ENaC internalization,
which facilitates destabilization of the cell surface ENaC
complex (78). It has also been found that the total activity,
functional expression, and open probability of ENaC in
mice underexpressing TGF-1 are all greater than those in
wild-type (46).
Protease nexin-1 (PN-1) has recently been found to inhibit
prostasin, which augments the activity of ENaC(8, 103). In-
triguingly, aldosterone and TGF-1 reciprocally regulate the
expressions of PN-1 and prostasin. Thus, prostasin expression
is increased by aldosterone and decreased by TGF-1, whereas
PN-1 expression is decreased by aldosterone and increased by
TGF-1 (103).
Aldosterone and TGF-1 differentially control the reabsorp-
tion of sodium in proximal tubular cells. Na-K-ATPase
1-subunits and mineralocorticoid receptors are expressed in
the proximal tubules of the mice, rats, and humans (87). The
activity of sodium/proton exchange is stimulated, and the
expression of sodium/proton exchanger 3 on the cell surface is
increased by aldosterone in cultured proximal tubular cells
(14). By contrast, Na-K-ATPase - and -subunit expres-
sion and Na-K-ATPase activity are dose dependently de-
creased by TGF-1 (73, 94).
Thus TGF-1 has been suggested to inhibit both aldosterone
production in the adrenal cortex and aldosterone actions in the
kidney. Although TGF-1 has been shown to directly increase
ROS in cultured cells (95), it counteracts production and action
of aldosterone, which enhance ROS generation and tissue
fibrosis (7, 65). Inhibition of aldosterone by TGF-1 may be a
negative feedback mechanism in diabetic nephropathy.
TGF-1 Suppresses Reabsorption of Water and Glucose in
Proximal Tubules
Notably, the urine volume in TGF-1 hypomorphic Akita
diabetic mice was comparable to that in nondiabetic wild-
type mice (31). In addition, the urinary output of glucose in
diabetes was substantially decreased by genetic insuffi-
ciency of TGF-1, despite unchanged plasma concentra-
tions of insulin and glucose. The marked reduction in
urinary water and glucose excretion by genetic insufficiency
of TGF-1 was also observed in their nondiabetic counter-
parts (31, 46). In addition, genetic disruption of Smad3,
which is the intracellular signaling molecule downstream of
TGF- receptors, also reduced urine volume despite little
change in plasma levels of glucose in STZ-induced diabetic
mice (19). These findings indicate that TGF-1 mediates
hyperglycemia-induced polyuria and glucosuria, which has
been attributed to osmotic diuresis.
The marked decrease in urinary water excretion in TGF-1
hypomorphic mice cannot be explained merely by enhanced
aldosterone function, because chronically high aldosterone
levels have been demonstrated to increase urine volume due to
impaired urine concentration ability (11). The diminished di-
uresis of the 10% hypomorphs was found to be fully reversed
by overexpressing Tgfb1 in the proximal tubule (31), and
partially restored by overexpressing Tgfb1 in the collecting
duct cells (our unpublished observations), indicating that
TGF-1 suppresses the reabsorption of water in both proximal
tubular cells and collecting ducts.
The finding that glucosuria and polyuria are both absent in
the TGF-1 hypomorphic diabetic mice may be related to the
previous observation that the sodium/glucose cotransporters
(SGLTs), which the proximal tubule highly expresses, cotrans-
port each sugar molecule with 200 water molecules (63). In
concordance with this inference, the urinary output of glucose
was partially restored in Akita mice with the expression of
Tgfb1 augmented in proximal tubules (31). Furthermore, high
glucose, hydrogen peroxide, and TGF-1 have been shown to
decrease the SGLT activity measured with -methyl-D-gluco-
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pyranoside, a metabolically inert analog of D-glucose, and
the expression of SGLT 1 and 2 and sodium-hydrogen
exchanger (NHE) 1 and 3 in primary cultured rabbit prox-
imal tubule cells, which is associated with genetic expres-
sion profile of EMT (57).
Although the chronic efficacy of the inhibitors of SGLT 1
and 2, which are being used for the purpose of controlling
blood glucose, on diabetic nephropathy is still controversial
(20, 102), several studies suggest that SGLT inhibitors prevent
cardiovascular and renal complications via reducing blood
glucose levels (49, 70). Thus the facts that both diabetes by
itself and TGF-1 decrease the reabsorption of glucose in
proximal tubular cells may be the compensatory mechanism
preventing further tissue damage.
Conclusion
A number of features of diabetic nephropathy were absent in
the TGF-1 hypomorphic Akita mice, indicating that decreas-
ing the expression of TGF-1 may have therapeutic benefits in
diabetics. However, the globally low expression of TGF-1
resulted in primary aldosteronism (31, 46). Consequently,
lowering the expression of TGF-1 throughout the body could
be deleterious in patients with diabetes. Nevertheless, these
problems of TGF-1 insufficiency might be circumvented if
kidney-specific reduction of the expression of TGF-1 were
achieved.
Experimental results with tissue-specific TGF-1 overex-
pression suggest that suppressing TGF-1 expression in the
proximal tubule is more likely to decrease albuminuria and
interstitial fibrosis than to prevent the decrease in renal excre-
tory function. In contrast, reducing expression of TGF-1 in
the podocyte may be more effective in avoiding the GFR
decrease than in decreasing albuminuria and interstitial fibro-
sis. Thus manipulations which lead to decreased TGF-1
expression in the podocyte may be useful for preventing/
treating the decline in renal function in diabetic nephropathy.
Further studies are needed to unravel the mechanisms for the
TGF-1-induced accumulation of ECM and for the suppres-
sion of the effects of mineralocorticoids by TGF-1, and this
understanding might be useful in developing new therapeutic
options for preventing and/or treating diabetic nephropathy.
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